EX-99.1 CHARTER 2 ex99.htm PRESS RELEASE

ex99.htm

	210, 1167 Kensington Cr. N.W.
	Calgary, Alberta
	Canada T2N 1X7

FOR IMMEDIATE RELEASE

Oncolytics Biotech® Inc. Announces Director Election Results from its Annual Meeting of Shareholders

CALGARY, AB, June 19, 2014 --- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that all nominees listed in the management information circular dated May 9, 2014 were elected as directors at its 2014 Annual Meeting of Shareholders, held on Wednesday June 18th, 2014. On a vote by ballot, the following 10 nominees proposed by management were elected as Directors of Oncolytics to serve until the Company`s next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favour of individual nominees as follows:

Director	For	%	Withheld	%
Ger van Amersfoort	13,138,482	93.53%	909,206	6.47%
Matthew Coffey	12,772,377	90.92%	1,275,312	9.08%
Jim Dinning	11,675,341	83.11%	2,372,347	16.89%
Linda Hohol	12,509,026	89.05%	1,538,662	10.95%
Angela Holtham	12,520,502	89.13%	1,527,186	10.87%
Ed Levy	12,369,473	88.05%	1,678,215	11.95%
Mark Lievonen	11,778,509	83.85%	2,269,179	16.15%
Wayne Pisano	13,090,751	93.19%	956,937	6.81%
Robert Schultz	12,849,006	91.47%	1,198,682	8.53%
Brad Thompson	12,299,004	87.55%	1,748,684	12.45%

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN®, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's belief as to the potential of REOLYSIN as a cancer therapeutic; the Company's expectations as to the success of its research and development programs in 2014 and beyond, the Company's planned operations, the value of the additional patents and intellectual property; the Company's expectations related to the applications of the patented technology; the Company's expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs; and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

FOR FURTHER INFORMATION PLEASE CONTACT:

The Equicom Group Nick Hurst 300 - 5th Ave. SW, 10th Floor Calgary, Alberta T2P 3C4 Tel: 403.218.2835 Fax: 403.218.2830 nhurst@equicomgroup.com Dian Griesel, Inc. Susan Forman 335 West 38th Street, 3rd Floor New York, NY  10018 Tel:  212.825.3210 Fax:  212.825.3229 sforman@dgicomm.com

-30-